Matches in Wikidata for { <http://www.wikidata.org/entity/Q92261844> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- Q92261844 description "article scientifique (publié 2019)" @default.
- Q92261844 description "artikull shkencor i botuar më 01 janar 2019" @default.
- Q92261844 description "artículu científicu espublizáu en xineru de 2019" @default.
- Q92261844 description "im Januar 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q92261844 description "scientific article published on 01 January 2019" @default.
- Q92261844 description "wetenschappelijk artikel" @default.
- Q92261844 description "наукова стаття, опублікована 1 січня 2019" @default.
- Q92261844 name "Cost-Effectiveness Analysis of Sunitinib versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore" @default.
- Q92261844 name "Cost-Effectiveness Analysis of Sunitinib versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore" @default.
- Q92261844 name "Cost-Effectiveness Analysis of Sunitinib versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore" @default.
- Q92261844 type Item @default.
- Q92261844 label "Cost-Effectiveness Analysis of Sunitinib versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore" @default.
- Q92261844 label "Cost-Effectiveness Analysis of Sunitinib versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore" @default.
- Q92261844 label "Cost-Effectiveness Analysis of Sunitinib versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore" @default.
- Q92261844 prefLabel "Cost-Effectiveness Analysis of Sunitinib versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore" @default.
- Q92261844 prefLabel "Cost-Effectiveness Analysis of Sunitinib versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore" @default.
- Q92261844 prefLabel "Cost-Effectiveness Analysis of Sunitinib versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore" @default.
- Q92261844 P1433 Q92261844-564B88F0-7668-4C7F-898B-B05EC1B30E06 @default.
- Q92261844 P1476 Q92261844-8AED9F07-0D52-472F-A052-5B2B9A617387 @default.
- Q92261844 P2093 Q92261844-1A5BCC9E-FEB8-49B0-9ECB-4155985005A6 @default.
- Q92261844 P2093 Q92261844-2AF27E3F-AA88-4926-8258-4E788C5FB240 @default.
- Q92261844 P2093 Q92261844-6DE4D540-3759-4E35-9538-47598BC32023 @default.
- Q92261844 P2093 Q92261844-78A26BB3-9BC4-4965-9C05-F9FFA1CFC3E9 @default.
- Q92261844 P2093 Q92261844-F8759E31-CD9B-4E0F-8D45-E6BF80B74E14 @default.
- Q92261844 P275 Q92261844-42126d54-958d-40ea-b7e2-b8c3b89fdaf0 @default.
- Q92261844 P2860 Q92261844-20F689D6-5FF9-408A-9ECF-880CBB4DA6C0 @default.
- Q92261844 P2860 Q92261844-2232364D-A1D2-4AE4-91F3-E9558B4A56C5 @default.
- Q92261844 P2860 Q92261844-31040958-50E9-4809-9851-7C82C0376483 @default.
- Q92261844 P2860 Q92261844-3E51F2D7-812C-4E97-98F3-85EF149E50E9 @default.
- Q92261844 P2860 Q92261844-50D9FDCC-38D1-4270-9984-5380EC33C88F @default.
- Q92261844 P2860 Q92261844-78993366-05CF-4182-925E-DA48BA3E6810 @default.
- Q92261844 P2860 Q92261844-9A9D280F-DCA6-4B46-9843-EB493C92E2E0 @default.
- Q92261844 P2860 Q92261844-A3767783-FFA6-48CD-9532-010D7CDBCF00 @default.
- Q92261844 P2860 Q92261844-C4823C93-A0F7-45C2-8787-EA55EB427CAE @default.
- Q92261844 P2860 Q92261844-CAA48582-CE7D-4837-92C4-D9FF517DA5A0 @default.
- Q92261844 P2860 Q92261844-FDE0BF14-61BA-4CAC-9134-7638D982D049 @default.
- Q92261844 P304 Q92261844-560561C3-1DFA-4ED3-A6A1-2186C420DB9B @default.
- Q92261844 P31 Q92261844-E13ACAC7-CF4E-4E21-A2B4-3286ABBFA44F @default.
- Q92261844 P356 Q92261844-0A6AFDB2-28B8-4297-A3F6-4C103D783810 @default.
- Q92261844 P433 Q92261844-A8F0EC1F-587B-4C1E-BE0F-1C57275703EE @default.
- Q92261844 P478 Q92261844-4ECBBA38-823C-42B0-B43B-BD02416893F1 @default.
- Q92261844 P50 Q92261844-0F8C4C75-E31E-43A6-B710-24D48CEA7FFD @default.
- Q92261844 P577 Q92261844-E0996AAD-5CD9-4F99-A2AF-E5A1F73F26FC @default.
- Q92261844 P6216 Q92261844-de79eb27-09cc-4927-8360-173f56c3d689 @default.
- Q92261844 P698 Q92261844-7CD7F3F8-AEF9-454C-A952-82FED06BB351 @default.
- Q92261844 P921 Q92261844-771570CB-F396-4161-A345-84F229BFF5CA @default.
- Q92261844 P921 Q92261844-812320A9-BE93-448D-82D8-4169BCC45543 @default.
- Q92261844 P356 S0266462319000059 @default.
- Q92261844 P698 30854989 @default.
- Q92261844 P1433 Q15750683 @default.
- Q92261844 P1476 "Cost-Effectiveness Analysis of Sunitinib versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore" @default.
- Q92261844 P2093 "David Bin-Chia Wu" @default.
- Q92261844 P2093 "Fiona Pearce" @default.
- Q92261844 P2093 "Kwong Ng" @default.
- Q92261844 P2093 "Min Han Tan" @default.
- Q92261844 P2093 "Mohamed Ismail Abdul Aziz" @default.
- Q92261844 P275 Q24082749 @default.
- Q92261844 P2860 Q28247085 @default.
- Q92261844 P2860 Q28282757 @default.
- Q92261844 P2860 Q33409916 @default.
- Q92261844 P2860 Q34148380 @default.
- Q92261844 P2860 Q37765246 @default.
- Q92261844 P2860 Q38550942 @default.
- Q92261844 P2860 Q43012853 @default.
- Q92261844 P2860 Q46423639 @default.
- Q92261844 P2860 Q46837791 @default.
- Q92261844 P2860 Q53659003 @default.
- Q92261844 P2860 Q87788903 @default.
- Q92261844 P304 "126-133" @default.
- Q92261844 P31 Q13442814 @default.
- Q92261844 P356 "10.1017/S0266462319000059" @default.
- Q92261844 P433 "2" @default.
- Q92261844 P478 "35" @default.
- Q92261844 P50 Q92261839 @default.
- Q92261844 P577 "2019-01-01T00:00:00Z" @default.
- Q92261844 P6216 Q50423863 @default.
- Q92261844 P698 "30854989" @default.
- Q92261844 P921 Q1164529 @default.
- Q92261844 P921 Q19000948 @default.